申请人:G. D. Searle & Co.
公开号:US05393747A1
公开(公告)日:1995-02-28
The present invention provides methods for treating convulsions, ischemia and other diseases responsive to prostaglandin-E.sub.2 antagonists in an animal comprising administering a therapeutically-effective amount of a substituted dibenzoxazepine compound of Formula I, or a pharmaceutically-acceptable salt thereof, to the animal: ##STR1## wherein Y is oxygen, sulfur, --SO-- or --SO.sub.2 --, R.sup.1 is hydrogen, halogen or --CF.sub.3, R.sup.2 is hydrogen, halogen, --OH or --OCH.sub.3, R.sup.3 is hydrogen, alkyl, aryl, alkyl-substituted aryl or aryl-substituted alkyl, m is an integer of from 1 to 5, X is ##STR2## R.sup.4 is hydrogen, alkyl, aryl, alkyl-substituted aryl, trifluoromethyl-substituted aryl or aryl-substituted alkyl, and R.sup.5 and R.sup.6 are each independently hydrogen, alkyl, aryl, alkyl-substituted aryl or aryl-substituted alkyl.
本发明提供了治疗惊厥、缺血和其他对前列腺素E.sub.2拮抗剂敏感的疾病的方法,包括向动物中投与式I的取代二苯并噻吩化合物或其药学上可接受的盐的治疗有效量:
##STR1##
其中,Y是氧、硫、--SO--或--SO.sub.2--,R.sup.1是氢、卤素或--CF.sub.3,R.sup.2是氢、卤素、--OH或--OCH.sub.3,R.sup.3是氢、烷基、芳基、烷基取代的芳基或芳基取代的烷基,m是1至5的整数,X是
##STR2##
R.sup.4是氢、烷基、芳基、烷基取代的芳基、三氟甲基取代的芳基或芳基取代的烷基,R.sup.5和R.sup.6各自独立地是氢、烷基、芳基、烷基取代的芳基或芳基取代的烷基。